CTLA4 and neoplasm: Only 1 case report by Jeena Chorath described a middle-aged female GB-NECs patient who achieved sustained relief of symptoms when treated with a combination of the PD-1 inhibitor(nivolumab), the CTLA-4 inhibitor(ipilimumab), and the EP chemotherapy regimen.[27] Generally, immune therapy is believed to be most effective in the inflammatory tumor microenvironment.